Antiangiogenic effects of melatonin in endothelial cell cultures

Microvascular Research

Volumn 87, Issue , 2013, Pages 25-33

  Alvarez García, Virginia ^a,b   González, Alicia ^a,b   Alonso González, Carolina ^a,b   Martínez Campa, Carlos ^a,b   Cos, Samuel ^a,b  

^a UNIVERSITY OF CANTABRIA   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MELATONIN; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL INVASION; CELL STRAIN MCF 7; CONTROLLED STUDY; CULTURE MEDIUM; HUMAN; HUMAN CELL; MIGRATION INHIBITION; PARACRINE SIGNALING; PRIORITY JOURNAL; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; BREAST NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; CULTURE MEDIA, CONDITIONED; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MCF-7 CELLS; MELATONIN; NEOVASCULARIZATION, PHYSIOLOGIC; PARACRINE COMMUNICATION; TIME FACTORS;

EID: 84876301766     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2013.02.008     Document Type: Article

References (45)

1. Alvarez-García V., González A., Alonso-González C., Martínez-Campa C., Cos S. Melatonin interferes in the desmoplastic reaction in breast cancer by regulating cytokine production. J. Pineal Res. 2012, 52:282-290.
2. Alvarez-García, V., González, A., Alonso-González, C., Martínez-Campa, C., Cos, S., in press. Regulation of vascular endothelial growth factor by melatonin in human breast cancer cells. J. Pineal Res. doi:10.1111/jpi.12007.
3. Banerjee S. The combination of VEGF inhibitors and anti-oestrogen therapies in breast cancer. Steroids 2011, 76:807-811.
4. Bareschino M.A., Schettino C., Colantuoni G., Rossi E., Rossi A., Maione P., Ciardiello F., Gridelli C. The role of antiangiogenic agents in the treatment of breast cancer. Curr. Med. Chem. 2011, 18:5022-5032.
5. Bergers G., Benjamin L.E. Tumorigenesis and the antiangiogenic switch. Nat. Rev. Cancer 2003, 3:401-410.
6. Blask D.E., Sauer L.A., Dauchy R.T. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr. Top. Med. Chem. 2002, 2:113-132.
7. Bochm T., Folkman J., Browder T., O'Reilly M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997, 390:404-407.
8. Cook K.M., Figg W.D. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J. Clin. 2010, 60:222-243.
9. Cos S., Sánchez-Barceló E.J. Melatonin and mammary pathological growth. Front. Neuroendocrinol. 2000, 21:133-170.
10. Cos S., Sánchez-Barceló E.J. Melatonin, experimental basis for a possible application in breast cancer prevention and treatment. Histol. Histopathol. 2000, 15:637-647.
11. Cos S., Fernández R., Güézmes A., Sánchez-Barceló E.J. Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res. 1998, 58:4383-4390.
12. Cos S., Martínez-Campa C., Mediavilla M.D., Sánchez-Barceló E.J. Melatonin modulates aromatase activity in MCF-7 human breast cancer cells. J. Pineal Res. 2005, 38:136-142.
13. Cos S., González A., Martínez-Campa C., Mediavilla M.D., Alonso-González C., Sánchez-Barceló E.J. Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions. Cancer Detect. Prev. 2006, 30:118-128.
14. Cos S., González A., Güezmes A., Mediavilla M.D., Martínez-Campa C., Alonso-González C., Sánchez-Barceló E.J. Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity. Int. J. Cancer 2006, 118:274-278.
15. Cos S., González A., Martínez-Campa C., Mediavilla M.D., Alonso-González C., Sánchez-Barceló E.J. Melatonin as a selective estrogen enzyme modulator. Curr. Cancer Drug Targets 2008, 8:691-702.
16. Cos S., González A., Alvarez-García V., Alonso-González C., Martínez-Campa C. Melatonin and breast cancer: selective estrogen enzyme modulator actions. Advances in Cancer Drug Targets 2012, vol. 1:207-237. Bentham Science Publishers, Sharjah, U.A.E. Atta-ur-Rahman (Ed.).
17. Cui P., Luo Z., Zhang H., Su Y., Li A., Li H., Zhang J., Yang Z., Xiu R. Effect and mechanism of melatonin's action on the proliferation of human umbilical vein endothelial cells. J. Pineal Res. 2006, 41:358-362.
18. Cui P., Yu M., Peng X., Dong L., Yang Z. Melatonin prevents human pancreatic carcinoma cell PANC-1-induced human vein endothelial cell proliferation and migration by inhibiting vascular endothelial growth factor expression. J. Pineal Res. 2012, 52:236-243.
19. 2 in cultured cancer cells. J. Pineal Res. 2008, 44:121-126.
20. Dvorak H.F., Weaver V.M., Tlsty T.D., Bergers G. Tumor microenvironment and progression. J. Surg. Oncol. 2011, 103:468-474.
21. García-Santos G., Antolín I., Herrera F., Martín V., Rodríguez-Blanco J., Carrera P., Rodríguez C. Melatonin induces apoptosis in human neuroblastoma cancer cells. J. Pineal Res. 2006, 41:130-135.
22. Gerber H.P., McMurtrey A., Kowalski J., Yan M., Keyt B.A., Dixit V., Ferrara N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 1998, 273:30336-30343.
23. Gingis-Velitski S., Zetser A., Flugelman M.Y., Vlodavsky I., Ilan N. Heparanase induces endothelial cell migration via protein kinase B/Akt activation. J. Biol. Chem. 2004, 279:23536-23541.
24. Giovannini M., Aldrighetti D., Zucchinelli P., Belli C., Villa E. Antiangiogenic strategies in breast cancer management. Crit. Rev. Oncol. Hematol. 2010, 76:13-35.
25. González A., Cos S., Martinez-Campa C., Alonso-González C., Sánchez-Mateos S., Mediavilla M.D., Sánchez-Barceló E.J. Selective estrogen enzyme modulator (SEEM) actions of melatonin in human breast cancer cells. J. Pineal Res. 2008, 45:86-92.
26. González A., Alvarez-García V., Martínez-Campa C., Alonso-González C., Cos S. Melatonin promotes differentiation of 3T3-L1 fibroblasts. J. Pineal Res. 2012, 52:12-20.
27. Gu Q., Wang D., Wang X., Peng R., Liu J., Jiang T., Wang Z., Wang S., Deng H. Basic fibroblast growth factor inhibits radiation-induced apoptosis of HUVECs. 1. The P13k/AKT pathway and induction of phosphorylation of BAD. Radiat. Res. 2004, 161:692-702.
28. Guo S., Colbert L.S., Fuller M., Zhang Y., González-Pérez R.R. Vascular endothelial growth factor receptor-2 in breast cancer. Biochim. Biophys. Acta 2010, 1806:108-121.
29. Hanahan D., Christofori G., Naik P., Arbeit J. Transgenic mouse models of tumor angiogenesis: the angiogenic switch, its molecular controls, and prospects of preclinical therapeutic models. Eur. J. Cancer 1996, 32A:2386-2393.
30. Hill S.M., Blask D.E. Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res. 1988, 48:6121-6126.
31. Kajdaniuk D., Marek B., Foltyn W., Kos-Kudla B. Vascular endothelial growth factor (VEGF) - Part 2: in endocrinology and oncology. Pol. J. Endocrinol. 2011, 62:456-464.
32. Liang Y., Hyder S.M. Proliferation of endothelial and tumor epithelial cells by progestin-induced vascular endothelial growth factor from human breast cancer cells: paracrine and autocrine effects. Endocrinology 2005, 146:3632-3641.
33. Lissoni P., Rovelli F., Malugani F., Bucovec R., Conti A., Maestroni G.J. Anti-angiogenic activity of melatonin in advanced cancer patients. Neuroendocrinol. Lett. 2001, 22:45-47.
34. Longatti P., Perin A., Rizzo V., Comai S., Giusti P., Costa C.V.L. Ventricular cerebrospinal fluid melatonin concentrations investigated with an endoscopic technique. J. Pineal Res. 2007, 42:113-118.
35. Maestroni J.M., Conti A. Melatonin in human breast cancer tissue: association with nuclear grade and estrogen receptor status. Lab. Invest. 1996, 75:557-561.
36. Martínez-Campa C., González A., Mediavilla M.D., Alonso-González C., Alvarez-García V., Sánchez-Barceló E.J., Cos S. Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells. Br. J. Cancer 2009, 101:1613-1619.
37. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
38. Park S.Y., Jang W.J., Yi E.Y., Jang J.Y., Jung Y., Jeong J.W., Kim Y.J. Melatonin suppresses tumor angiogenesis by inhibiting HIF-1α stabilization under hypoxia. J. Pineal Res. 2010, 48:178-184.
39. Sainz R.M., Mayo J.C., Tan D.X., Leon J., Manchester L., Reiter R.J. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. Prostate 2005, 63:29-43.
40. Salven P., Mänpää H., Orpana A., Alitalo K., Joensuu H. Serum vascular endothelial growth factor is often evaluated in disseminated cancer. Clin. Cancer Res. 1997, 3:647-651.
41. Sánchez-Barceló E.J., Cos S., Fernández R., Mediavilla M.D. Melatonin and mammary cancer: a short review. Endocr. Relat. Cancer 2003, 10:153-159.
42. Sánchez-Barceló E.J., Cos S., Mediavilla M.D., Martínez-Campa C., González A., Alonso-González C. Melatonin-estrogen interactions in breast cancer. J. Pineal Res. 2005, 38:217-222.
43. Senger D.R., Van de Water L., Brown L.F., Nagy J.A., Yeo K.T., Yeo T.K., Berse B., Jackman R.W., Dvorak A.M., Dvorak H.F. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 1993, 12:303-324.
44. Staton C.A., Stribbling S.M., Tazzyman S., Hughes R., Brown N.J., Lewis C.E. Current methods for assaying angiogenesis in vitro and in vivo. Int. J. Exp. Pathol. 2004, 85:233-248.
45. Yoshiji H., Gomez D.E., Shibuya M., Thorgeirsson U.P. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res. 1996, 56:2013-2016.